The coexistence of BRAFV600E and telomerase reverse transcriptase (TERT) promoter alterations has been reported to cooperatively upregulate TERT expression and is well recognized as a biomarker for aggressive thyroid cancer. However, the mechanism underlying their synergistic effect remains elusive.
Methods:
TERT-interacting proteins were identified via immunoprecipitation (IP) and mass spectrometry and validated by Co-IP. DDX21 expression was detected in 60 paired thyroid cancer and adjacent normal tissues, and the function of DDX21 in thyroid cancer was explored in vitro and in vivo. Integrated analyses of RNA-seq, ChIP-seq, and Ribo-seq assays were conducted to elucidate the molecular mechanisms. BRAF/MEK inhibitors and BRAFV600E overexpression were used to investigate the regulation of DDX21 by BRAF mutation. In silico analysis, ChIP, and luciferase reporter assays were used to identify the transcription factors binding to DDX21 promoter.
Results:
DDX21 interacted with TERT to regulate ribosomal RNA (rRNA) transcription by affecting the binding of Pol I to rDNA. DDX21 is upregulated in thyroid cancer, and DDX21 knockdown decreased the expression of multiple cancer hallmark genes and suppressed cell proliferation, colony formation, cell migration, and invasion of thyroid cancer cells. GABPA bound to the promoter of DDX21, and knockdown of GABPA or GABPB1 suppressed DDX21 promoter activity and transcription. Pharmacological inhibition of the MAPK pathway in BRAF-mutant cancer cells decreased the expression of GABPA, GABPB1, and DDX21.
Conclusions:
BRAFV600E upregulates expression of DDX21 through the MEK/ERK/GABP axis. DDX21, in turn, interacts with TERT to promote rRNA transcription and modulate the expression of multiple cancer hallmark genes, driving the malignant progression of thyroid cancer. These findings suggest that DDX21 acts as a mediator to bridge the crosstalk between BRAFV600E and TERT and may serve as a therapeutic target for patients with thyroid cancer harboring BRAF and TERT alterations.
WanPT, GarnettMJ, RoeSM, et al.; Cancer Genome Project. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell, 2004; 116(6):855–867; doi: 10.1016/s0092-8674(04)00215-6
4.
XingM. BRAF mutation in papillary thyroid cancer: Pathogenic role, molecular bases, and clinical implications. Endocr Rev, 2007; 28(7):742–762; doi: 10.1210/er.2007-0007
5.
CabanillasME, RyderM, JimenezC. Targeted therapy for advanced thyroid cancer: Kinase inhibitors and beyond. Endocr Rev, 2019; 40(6):1573–1604; doi: 10.1210/er.2019-00007
6.
PoulikakosPI, SullivanRJ, YaegerR. Molecular pathways and mechanisms of BRAF in cancer therapy. Clin Cancer Res, 2022; 28(21):4618–4628; doi: 10.1158/1078-0432.Ccr-21-2138
BullockM, LimG, ZhuY, et al.ETS factor ETV5 activates the mutant telomerase reverse transcriptase promoter in thyroid cancer. Thyroid, 2019; 29(11):1623–1633; doi: 10.1089/thy.2018.0314
9.
WuY, ShiL, ZhaoY, et al.Synergistic activation of mutant TERT promoter by Sp1 and GABPA in BRAF(V600E)-driven human cancers. NPJ Precis Oncol, 2021; 5(1):3; doi: 10.1038/s41698-020-00140-5
10.
ThorntonCEM, HaoJ, TamarapuPP, et al.Multiple ETS factors participate in the transcriptional control of TERT mutant promoter in thyroid cancers. Cancers (Basel), 2022; 14(2):357; doi: 10.3390/cancers14020357
LiuR, ZhangT, ZhuG, et al.Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer. Nat Commun, 2018; 9(1):579; doi: 10.1038/s41467-018-03033-1
13.
LandaI, IbrahimpasicT, BoucaiL, et al.Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest, 2016; 126(3):1052–1066; doi: 10.1172/jci85271
14.
XuB, FuchsT, DoganS, et al.Dissecting anaplastic thyroid carcinoma: A comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases. Thyroid, 2020; 30(10):1505–1517; doi: 10.1089/thy.2020.0086
15.
ZengPYF, ProkopecSD, LaiSY, et al.The genomic and evolutionary landscapes of anaplastic thyroid carcinoma. Cell Rep, 2024; 43(3):113826; doi: 10.1016/j.celrep.2024.113826
16.
HuG, XueJ, YuJ, et al.High prevalence of TBC1D12 5′UTR mutations in anaplastic thyroid cancer. Thyroid, 2025; 35(1):115–119; doi: 10.1089/thy.2024.0345
17.
MeloM, da RochaAG, VinagreJ, et al.TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab, 2014; 99(5):E754–E765; doi: 10.1210/jc.2013-3734
18.
GeorgeJR, HendersonYC, WilliamsMD, et al.Association of TERT promoter mutation, but not braf mutation, with increased mortality in PTC. J Clin Endocrinol Metab, 2015; 100(12):E1550–E9; doi: 10.1210/jc.2015-2690
19.
KimTH, KimYE, AhnS, et al.TERT promoter mutations and long-term survival in patients with thyroid cancer. Endocr Relat Cancer, 2016; 23(10):813–823; doi: 10.1530/erc-16-0219
20.
YangX, LiJ, LiX, et al.TERT promoter mutation predicts radioiodine-refractory character in distant metastatic differentiated thyroid cancer. J Nucl Med, 2017; 58(2):258–265; doi: 10.2967/jnumed.116.180240
21.
YangH, ParkH, RyuHJ, et al.Frequency of TERT promoter mutations in real-world analysis of 2,092 thyroid carcinoma patients. Endocrinol Metab (Seoul), 2022; 37(4):652–663; doi: 10.3803/EnM.2022.1477
22.
LeeDD, LeãoR, KomosaM, et al.DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. J Clin Invest, 2019; 129(1):223–229; doi: 10.1172/jci121303
23.
LiS, HuG, ChenY, et al.TERT upstream promoter methylation regulates TERT expression and acts as a therapeutic target in TERT promoter mutation-negative thyroid cancer. Cancer Cell Int, 2024; 24(1):271; doi: 10.1186/s12935-024-03459-2
24.
LiS, XueJ, JiangK, et al.TERT promoter methylation is associated with high expression of TERT and poor prognosis in papillary thyroid cancer. Front Oncol, 2024; 14:1325345; doi: 10.3389/fonc.2024.1325345
25.
SangY, HuG, XueJ, et al.Risk stratification by combining common genetic mutations and TERT promoter methylation in papillary thyroid cancer. Endocrine, 2024; 85(1):304–312; doi: 10.1007/s12020-024-03722-6
26.
SongYS, LimJA, ChoiH, et al.Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients. Cancer, 2016; 122(9):1370–1379; doi: 10.1002/cncr.29934
27.
LiuR, BishopJ, ZhuG, et al.Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer: Genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality. JAMA Oncol, 2017; 3(2):202–208; doi: 10.1001/jamaoncol.2016.3288
28.
LiuR, ZhuG, TanJ, et al.Genetic trio of BRAF and TERT alterations and rs2853669TT in papillary thyroid cancer aggressiveness. J Natl Cancer Inst, 2024; 116(5):694–701; doi: 10.1093/jnci/djad265
29.
LiuR, TanJ, ShenX, et al.Therapeutic targeting of FOS in mutant TERT cancers through removing TERT suppression of apoptosis via regulating survivin and TRAIL-R2. Proc Natl Acad Sci U S A, 2021; 118(11):e2022779118; doi: 10.1073/pnas.2022779118
30.
GonzalezOG, AssfalgR, KochS, et al.Telomerase stimulates ribosomal DNA transcription under hyperproliferative conditions. Nat Commun, 2014; 5:4599; doi: 10.1038/ncomms5599
31.
KhattarE, KumarP, LiuCY, et al.Telomerase reverse transcriptase promotes cancer cell proliferation by augmenting tRNA expression. J Clin Invest, 2016; 126(10):4045–4060; doi: 10.1172/jci86042
LandaI, ThorntonCEM, XuB, et al.Telomerase upregulation induces progression of mouse BrafV600E-driven thyroid cancers and triggers nontelomeric effects. Mol Cancer Res, 2023; 21(11):1163–1175; doi: 10.1158/1541-7786.Mcr-23-0144
34.
YuP, QuN, ZhuR, et al.TERT accelerates BRAF mutant-induced thyroid cancer dedifferentiation and progression by regulating ribosome biogenesis. Sci Adv, 2023; 9(35):eadg7125; doi: 10.1126/sciadv.adg7125
35.
XiaoX, ChenM, SangY, et al.Methylation-mediated silencing of ATF3 promotes thyroid cancer progression by regulating prognostic genes in the MAPK and PI3K/AKT pathways. Thyroid, 2023; 33(12):1441–1454; doi: 10.1089/thy.2023.0157
36.
TuttleRM, HaugenB, PerrierND. Updated American Joint Committee on cancer/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (eighth edition): What changed and why? Thyroid, 2017; 27(6):751–756; doi: 10.1089/thy.2017.0102
37.
RingelMD, SosaJA, BalochZ, et al.2025 American Thyroid Association Management Guidelines for adult patients with differentiated thyroid cancer. Thyroid, 2025; 35(8):841–985; doi: 10.1177/10507256251363120
38.
ChenY, SangY, LiS, et al.The ERK inhibitor GDC-0994 selectively inhibits growth of BRAF mutant cancer cells. Transl Oncol, 2024; 45:101991; doi: 10.1016/j.tranon.2024.101991
39.
IngoliaNT, BrarGA, RouskinS, et al.The ribosome profiling strategy for monitoring translation in vivo by deep sequencing of ribosome-protected mRNA fragments. Nat Protoc, 2012; 7(8):1534–1550; doi: 10.1038/nprot.2012.086
40.
WangT, CuiY, JinJ, et al.Translating mRNAs strongly correlate to proteins in a multivariate manner and their translation ratios are phenotype specific. Nucleic Acids Res, 2013; 41(9):4743–4754; doi: 10.1093/nar/gkt178
41.
LiY, ChengHS, ChngWJ, et al.Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas. Proc Natl Acad Sci U S A, 2016; 113(50):14402–14407; doi: 10.1073/pnas.1611106113
42.
CaoY, LiH, DebS, et al.TERT regulates cell survival independent of telomerase enzymatic activity. Oncogene, 2002; 21(20):3130–3138; doi: 10.1038/sj.onc.1205419
43.
RedonS, ReichenbachP, LingnerJ. Protein RNA and protein protein interactions mediate association of human EST1A/SMG6 with telomerase. Nucleic Acids Res, 2007; 35(20):7011–7022; doi: 10.1093/nar/gkm724
44.
PanditaRK, ChowTT, UdayakumarD, et al.Single-strand DNA-binding protein SSB1 facilitates TERT recruitment to telomeres and maintains telomere G-overhangs. Cancer Res, 2015; 75(5):858–869; doi: 10.1158/0008-5472.Can-14-2289
45.
CaloE, FlynnRA, MartinL, et al.RNA helicase DDX21 coordinates transcription and ribosomal RNA processing. Nature, 2015; 518(7538):249–253; doi: 10.1038/nature13923
46.
SawadaJ, GotoM, SawaC, et al.Transcriptional activation through the tetrameric complex formation of E4TF1 subunits. Embo J, 1994; 13(6):1396–1402; doi: 10.1002/j.1460-2075.1994.tb06393.x
47.
SternJL, TheodorescuD, VogelsteinB, et al.Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers. Genes Dev, 2015; 29(21):2219–2224; doi: 10.1101/gad.269498.115
48.
ChenB, ShiY, XuY, et al.The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A systematic review and meta-analysis. Clin Endocrinol (Oxf), 2021; 94(5):731–742; doi: 10.1111/cen.14316
49.
CiminoD, FusoL, SfiligoiC, et al.Identification of new genes associated with breast cancer progression by gene expression analysis of predefined sets of neoplastic tissues. Int J Cancer, 2008; 123(6):1327–1338; doi: 10.1002/ijc.23660
50.
WangK, LiB, FanP, et al.Downregulation of DEAD-box helicase 21 (DDX21) inhibits proliferation, cell cycle, and tumor growth in colorectal cancer via targeting cell division cycle 5-like (CDC5L). Bioengineered, 2021; 12(2):12647–12658; doi: 10.1080/21655979.2021.2011636
51.
KoltowskaK, OkudaKS, GlogerM, et al.The RNA helicase Ddx21 controls Vegfc-driven developmental lymphangiogenesis by balancing endothelial cell ribosome biogenesis and p53 function. Nat Cell Biol, 2021; 23(11):1136–1147; doi: 10.1038/s41556-021-00784-w
52.
CaoJ, WuN, HanY, et al.DDX21 promotes gastric cancer proliferation by regulating cell cycle. Biochem Biophys Res Commun, 2018; 505(4):1189–1194; doi: 10.1016/j.bbrc.2018.10.060
53.
PutraV, HulmeAJ, TeeAE, et al.The RNA-helicase DDX21 upregulates CEP55 expression and promotes neuroblastoma. Mol Oncol, 2021; 15(4):1162–1179; doi: 10.1002/1878-0261.12906
54.
XingYH, YaoRW, ZhangY, et al.SLERT regulates DDX21 rings associated with Pol I transcription. Cell, 2017; 169(4):664–678 e16; doi: 10.1016/j.cell.2017.04.011
55.
YangH, ZhouJ, OchsRL, et al.Down-regulation of RNA helicase II/Gu results in the depletion of 18 and 28 S rRNAs in Xenopus oocyte. J Biol Chem, 2003; 278(40):38847–38859; doi: 10.1074/jbc.M302258200
56.
HolmstromTH, MialonA, KallioM, et al.c-Jun supports ribosomal RNA processing and nucleolar localization of RNA helicase DDX21. J Biol Chem, 2008; 283(11):7046–7053; doi: 10.1074/jbc.M709613200
57.
TangW, YangY, FuZ, et al.The RNA helicase DDX21 activates YAP to promote tumorigenesis and is transcriptionally upregulated by β-catenin in colorectal cancer. Oncogene, 2024; 43(44):3227–3239; doi: 10.1038/s41388-024-03160-8
58.
Manrique-SilvaE, RachakondaS, Millán-EstebanD, et al.Clinical, environmental and histological distribution of BRAF, NRAS and TERT promoter mutations among patients with cutaneous melanoma: A retrospective study of 563 patients. Br J Dermatol, 2021; 184(3):504–513; doi: 10.1111/bjd.19297
59.
RosenbergT, YeoKK, MauguenA, et al.Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma. Neuro Oncol, 2022; 24(11):1964–1975; doi: 10.1093/neuonc/noac096
60.
XingM, LiuR, LiuX, et al.BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol, 2014; 32(25):2718–2726; doi: 10.1200/jco.2014.55.5094
61.
LiuJ, LiuR, ShenX, et al.The genetic duet of BRAF V600E and TERT promoter mutations robustly predicts loss of radioiodine avidity in recurrent papillary thyroid cancer. J Nucl Med, 2020; 61(2):177–182; doi: 10.2967/jnumed.119.227652
62.
XingM, LinS, MathurA, et al.Genetic modification of the AJCC classification of papillary thyroid cancer: An international, multicentre, retrospective cohort study. Lancet Oncol, 2025; 26(10):1382–1392; doi: 10.1016/s1470-2045(25)00399-7
63.
ItoS, YokoyamaU, NakakojiT, et al.Fibulin-1 integrates subendothelial extracellular matrices and contributes to anatomical closure of the ductus arteriosus. Arterioscler Thromb Vasc Biol, 2020; 40(9):2212–2226; doi: 10.1161/atvbaha.120.314729
64.
Adorno-CruzV, LiuH. Regulation and functions of integrin α2 in cell adhesion and disease. Genes Dis, 2019; 6(1):16–24; doi: 10.1016/j.gendis.2018.12.003
65.
ZhaoY, XuJ, YouY, et al.ID1 in hematopoiesis and hematologic disorders: Novel potentials of a classic differentiation regulator. Cell Mol Biol Lett, 2025; 30(1):124; doi: 10.1186/s11658-025-00801-y
66.
LykoF. The DNA methyltransferase family: A versatile toolkit for epigenetic regulation. Nat Rev Genet, 2018; 19(2):81–92; doi: 10.1038/nrg.2017.80
67.
MatthewsHK, BertoliC, de BruinRAM. Cell cycle control in cancer. Nat Rev Mol Cell Biol, 2022; 23(1):74–88; doi: 10.1038/s41580-021-00404-3
68.
ChenZ, LiZ, HuX, et al.Structural basis of human helicase DDX21 in RNA binding, unwinding, and antiviral signal activation. Adv Sci (Weinh), 2020; 7(14):2000532; doi: 10.1002/advs.202000532
69.
BohnsackKE, YiS, VenusS, et al.Cellular functions of eukaryotic RNA helicases and their links to human diseases. Nat Rev Mol Cell Biol, 2023; 24(10):749–769; doi: 10.1038/s41580-023-00628-5
70.
CristofanilliM, RugoHS, ImSA, et al.Overall survival with palbociclib and fulvestrant in women with HR+/HER2- ABC: Updated exploratory analyses of PALOMA-3, a double-blind, Phase III randomized study. Clin Cancer Res, 2022; 28(16):3433–3442; doi: 10.1158/1078-0432.Ccr-22-0305
71.
LeeHJ, LeeWK, KangCW, et al.A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer. Cancer Lett, 2018; 417:131–140; doi: 10.1016/j.canlet.2017.12.037
72.
FuS, YaoS, YuanY, et al.Multicenter Phase II trial of the WEE1 inhibitor adavosertib in refractory solid tumors harboring CCNE1 amplification. J Clin Oncol, 2023; 41(9):1725–1734; doi: 10.1200/jco.22.00830
73.
XiaoR, YouL, ZhangL, et al.Inhibiting the IRE1α axis of the unfolded protein response enhances the antitumor effect of AZD1775 in TP53 mutant ovarian cancer. Adv Sci (Weinh), 2022; 9(21):e2105469; doi: 10.1002/advs.202105469
74.
LiJ, LuJ, XuM, et al.ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer models. J Clin Invest, 2023; 133(2):e161544; doi: 10.1172/jci161544
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
